Yes, I share that concern. I don't think that's going to be the impact. I think companies can afford to bring their products to Canada. I don't think the Canadian price has to be the highest in the world for companies to make a profit in the Canadian market. I don't understand that argument.
One of the things we're putting in place, now that we're close to the implementation date, is a comprehensive monitoring and evaluation plan. We will be looking at benchmarks today. Currently we're 13th in terms of access. We get about 50% of new substances that come to the market in any given year, notwithstanding that we have very high prices. We're going to be looking at the impact over time of these changes. Is access going down or going up? If it's going down dramatically, do we need to make adjustments?
Canada is not unique in struggling to find a socially acceptable price for products like Trikafta and other cystic fibrosis—
I'm sorry. I think I've answered your question. I don't want to take up too much time with my responses.